Evercore ISI Initiates Coverage of Abbott, Hologic, Becton Dickinson at Outperform

Jan 03, 2018

|

NEW YORK (GenomeWeb) – Investment bank Evercore ISI said today that it has initiated coverage of Abbott with an Outperform rating and target price of $64 per share, Hologic with an Outperform rating and a target price of $50 per share, and Becton Dickinson with an Outperform rating and a target price of $245 per share.

Evercore ISI analyst Vijay Kumar said that initiating coverage of the three diagnostic companies coincides with re-initiating coverage of the medical technology (MedTech) sector.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Evercore ISI Initiates Coverage of Abbott, Hologic, Becton Dickinson at Outperform

To read the full story....

Breaking News

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

What's Popular?

BARDA Awards $5.4M to Luminex for Expanded Respiratory Panel With Coronavirus Target

FDA Grants Emergency Use Authorization for Jiangsu Well Biotech Coronavirus Antibody Test

Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

FDA Grants Emergency Use Authorizations for Quadrant Biosciences, KimForest Coronavirus Tests

Sponsorships